1. Home
  2. INTT vs MGNX Comparison

INTT vs MGNX Comparison

Compare INTT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo inTest Corporation

INTT

inTest Corporation

HOLD

Current Price

$18.37

Market Cap

234.0M

Sector

Technology

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$3.16

Market Cap

220.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTT
MGNX
Founded
1981
2000
Country
United States
United States
Employees
407
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
234.0M
220.6M
IPO Year
1997
2013

Fundamental Metrics

Financial Performance
Metric
INTT
MGNX
Price
$18.37
$3.16
Analyst Decision
Strong Buy
Buy
Analyst Count
2
5
Target Price
$13.50
$5.00
AVG Volume (30 Days)
294.8K
720.9K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$66,801,000.00
$149,500,000.00
Revenue This Year
$15.82
N/A
Revenue Next Year
$9.10
$3.19
P/E Ratio
N/A
N/A
Revenue Growth
66.06
N/A
52 Week Low
$5.64
$1.19
52 Week High
$20.00
$3.88

Technical Indicators

Market Signals
Indicator
INTT
MGNX
Relative Strength Index (RSI) 64.14 50.88
Support Level $7.37 $1.45
Resistance Level N/A $3.26
Average True Range (ATR) 1.60 0.20
MACD 0.11 -0.06
Stochastic Oscillator 73.15 31.29

Price Performance

Historical Comparison
INTT
MGNX

About INTT inTest Corporation

inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: